Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 7/20 | 0.67 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pteroic Acid SCHEMBL16047869 | 0.99 | DHFR (0.66) | DHFRCA1CA2CA9KDM4E | |
| Pteroic Acid SCHEMBL28022366 | 0.99 | DHFR (0.66) | DHFRCA1CA2CA9KDM4E | |
| Pteroic Acid SCHEMBL27919717 | 0.99 | DHFR (0.66) | DHFRCA1CA2CA9KDM4E | |
| SCHEMBL13683833 | 0.92 | DHFR (0.63) | DHFRCA1CA2CA9 | |
| SCHEMBL20647289 | 0.91 | DHFR (0.62) | DHFRCA1CA2CA9 | |
| SCHEMBL12867919 | 0.91 | DHFR (0.65) | DHFRCA1CA2CA9KDM4E | |
| SCHEMBL14417311 | 0.91 | DHFR (0.81) | DHFRCA1CA2CA9 | |
| SCHEMBL28985427 | 0.89 | DHFR (0.80) | DHFRCA1CA2CA9 | |
| SCHEMBL20806703 | 0.89 | DHFR (0.60) | DHFRCA1CA2CA9KDM4E | |
| SCHEMBL19997525 | 0.89 | DHFR (0.60) | DHFRCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| WO-2025092703-A1 | PHOTOSENSITIZER CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 同宜医药（苏州）有限公司 | 2025-05-08 | — | — | WO | claimed |
| CN-119869477-A | Adsorption column packing and application thereof | 徐霖南 | 2025-04-25 | — | — | CN | claimed |
| CN-119855612-A | Radionuclide coupling medicine, pharmaceutical composition and application thereof | 同宜医药（苏州）有限公司 | 2025-04-18 | — | — | CN | claimed |
| EP-4512426-A1 | COMPOUND AND USE THEREOF | Coherent Biopharma (Suzhou), Limited (CN) | 2025-02-26 | — | — | EP | claimed |
| CN-119031938-A | Compounds and uses | 同宜医药（苏州）有限公司 | 2024-11-26 | — | — | CN | claimed |
| WO-2024155082-A1 | BIODEGRADABLE POLYESTER RESIN COMPOSITION, PREPARATION METHOD TEHREFOR, BIODEGRADABLE POLYESTER FILM COMPRISING SAME, AND BIODEGRADABLE POLYESTER MOLDED ARTICLE COMPRISING SAME | 에스케이리비오 주식회사 | 2024-07-25 | — | — | WO | claimed |
| CN-116376016-B | Preparation method and application of artificial melanin nanofiber with fluorescence | 四川大学 | 2024-03-29 | — | — | CN | claimed |
| WO-2024051794-A1 | RADIONUCLIDE-DRUG CONJUGATE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 同宜医药（苏州）有限公司 | 2024-03-14 | — | — | WO | claimed |
| CN-117388398-A | Detection method of B vitamins | 华熙生物科技股份有限公司 | 2024-01-12 | — | — | CN | claimed |
| WO-1996027572-A1 | METHODS AND COMPOSITIONS FOR ENHANCING FORMYLTETRAHYDROPTEROYLPOLYGLUTAMATE IN PLANTS | NONOMURA ARTHUR M (US) | 1996-09-12 | — | — | WO | claimed |
| EP-0686263-A1 | COMPETITIVE IMMUNOASSAY UTILIZING BINDING PROTEIN IN A MULTICLONAL ANTIBODY FORMAT | ABBOTT LABORATORIES (US) | 1995-12-13 | — | — | EP | claimed |
| US-5434087-A | Folate immunoassay utilizing folate binding protein in a multiclonal antibody format | ABBOTT LABORATORIES (US) | 1995-07-18 | — | — | US | claimed |
| US-5374726-A | Coupling substituted diester with 6-methylene halide of selected deazaaminopterin, hydrolyzing ester groups, removing carboxylic acid attached to alpha carbon | DEGRAW JOSEPH I (US) | 1994-12-20 | — | — | US | claimed |
| WO-1994019695-A1 | COMPETITIVE IMMUNOASSAY UTILIZING BINDING PROTEIN IN A MULTICLONAL ANTIBODY FORMAT | ABBOTT LABORATORIES (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0251455-B1 | Amine derivatives of folic acid analogs | CYTOGEN CORP (US) | 1994-05-11 | — | — | EP | claimed |
| WO-1993022316-A1 | PROCESS FOR PREPARING 10-DEAZAAMINOPTERINS AND 5,10- AND 8,10-DIDEAZAAMINOPTERINS FROM PTEROIC DICARBOXYLIC ACID DIESTERS | SRI INTERNATIONAL (US) | 1993-11-11 | — | — | WO | claimed |
| EP-0251455-A2 | Amine derivatives of folic acid analogs | CYTOGEN CORPORATION (US) | 1988-01-07 | — | — | EP | claimed |
| US-4433147-A | ALKYLATION CARBO ACID WITH 3-CHLORO-1-METHOXY-PROPENE, BROMOACYLATION, REACTING WITH 2,4,5,6-TETRACAMINOPYRIMIDINE, CYCLIZATION AND DEHYDROGENATION | DEGRAW JR JOSEPH I (US) | 1984-02-21 | — | — | US | claimed |
| US-4337339-A | Process for preparation of folic acid derivatives | BAKER INSTRUMENTS CORP. (US) | 1982-06-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | DHFR 501/4885CA1 173/4885CA2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.